1. Home
  2. GOCO vs SKYE Comparison

GOCO vs SKYE Comparison

Compare GOCO & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GoHealth Inc.

GOCO

GoHealth Inc.

HOLD

Current Price

$1.76

Market Cap

38.3M

Sector

Finance

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.73

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOCO
SKYE
Founded
2001
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.3M
44.9M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
GOCO
SKYE
Price
$1.76
$0.73
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
$5.00
$14.75
AVG Volume (30 Days)
37.9K
322.2K
Earning Date
02-26-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$738,338,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.56
N/A
52 Week Low
$1.83
$0.68
52 Week High
$21.00
$5.75

Technical Indicators

Market Signals
Indicator
GOCO
SKYE
Relative Strength Index (RSI) 32.47 33.10
Support Level $1.83 $0.78
Resistance Level $2.10 $1.07
Average True Range (ATR) 0.16 0.08
MACD -0.03 -0.02
Stochastic Oscillator 1.35 9.33

Price Performance

Historical Comparison
GOCO
SKYE

About GOCO GoHealth Inc.

GoHealth Inc is a health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers' peace of mind when making healthcare decisions so consumers can focus on living life. It offers Medicare plans, including, but not limited to, Medicare Advantage, Medicare Supplement and prescription drug plans. Its proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer's specific needs.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: